Skip to content

Cardiovascular risk in gout

The effect of acute gout on High-risk rupture-prone plaques (HRPs) determined by coronary computed tomography angiography (CCTA)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12619001764123
Acronym
CRIG
Enrollment
0
Registered
2019-12-11
Start date
2019-12-16
Completion date
2020-04-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to assess the cardiovascular risk in people with gout, through performing scanning the heart, and then performing the scan in 6 months. We will determine the impact of having an acute flare of gout on the scans, which is a surrogate of cardiovascular risk. This will help us understand the effect of acute inflammation on cardiovascular risk in gout,

Interventions

The exposure is an attack of acute gout. We will do patient questionnaires, metrology(swollen and tender joint count), blood tests, a Coronary CT Angiogram. The total duration of follow-up for each patient is 6 months. Patients will be assessed monthly, the first and last visit might last hour, the other visits will last about 20 minutes.

Sponsors

Fiona Stanley Hospital
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

A diagnosis of gout according to 2015 ACR criteria requiring allopurinol therapy 45 years and a minimum of 2 risk factors, i.e. controlled hypertension, controlled diabetes, controlled dyslipidemia, obesity, age >55 years, and first degree relative with evidence of atherosclerosis <65 years will be recruited.

Exclusion criteria

Other forms of inflammatory arthritis (especially rheumatoid arthritis and psoriasis Moderate to severe hepatic impairment moderate renal impairment Contra indication to allopurinol, especially azathioprine or 6-mercaptopurine use. Pregnancy or breastfeeding. Presence of any serious medical illness that may preclude follow up. Inability to provide informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026